Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors.
Am J Cardiol
; 110(7): 1001-7, 2012 Oct 01.
Article
em En
| MEDLINE
| ID: mdl-22742717
ABSTRACT
Previous studies have demonstrated that ß-adrenergic receptor polymorphisms affect outcomes in patients with heart failure or after an acute coronary syndrome. Whether ß-adrenergic polymorphisms influence catecholamine responses in patients with cardiovascular disease is not known. Cardiovascular responses to the ß1-receptor agonist dobutamine and the ß2-receptor agonist terbutaline were studied using gated blood pool scintigraphy in 21 patients on long-term ß-blocker therapy. Heart rate (HR), stroke volume (SV), and cardiac output (CO) increased, and end-systolic volume decreased with dobutamine and terbutaline. Changes in HR and CO with dobutamine were higher for those with ≥1 ß1 Arg389 allele than those homozygous for the Gly389 allele (change in HR 15 vs 1 beat/min, p = 0.02; change in CO 2.4 vs 1.0 L/min, p = 0.02). Increases in HR, CO, and SV with terbutaline were greater for those homozygous for the ß2 Glu27 allele than those with ≥1 Gln27 allele (change in HR 13.7 vs 4.8 beats/min, p = 0.048; change in CO 3.1 vs 1.6 L/min, p = 0.034; change in SV 28.3 vs 14.8 ml, p = 0.045). Changes in CO and volume with terbutaline were greater in those with an ejection fraction <40% than in those with an ejection fraction ≥40%. In conclusion, ß-receptor gene variants significantly influence inotropic and chronotropic responses to ß-agonist exposure in patients on ß-blocker therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polimorfismo Genético
/
DNA
/
Catecolaminas
/
Receptores Adrenérgicos beta 2
/
Receptores Adrenérgicos beta 1
/
Insuficiência Cardíaca
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article